Search This Blog

Monday, August 10, 2026

Oruka Q2 2026 net loss $41.2M (EPS -0.55) and $1.1B cash funds operations through BLA filing

 

Oruka Therapeutics Q2 2026 net loss $41.2M (EPS -0.55) and $1.1B cash funds operations through ORKA-001 BLA filing

  • Non-GAAP EPS was -0.55 in Q2 2026, down 20% YoY and missing EPS estimates
  • Q2 2026 revenue was $0, beating revenue estimates
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)